ODALASVIR

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C60H72N8O6
Molecular Weight	1001.2637
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)N[C@@H](C(C)C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=CC=C(C=C4N3)C5=CC6=CC=C5CCC7=CC=C(CC6)C(=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]%10C[C@@H]%11CCCC[C@@H]%11N%10C(=O)[C@@H](NC(=O)OC)C(C)C

InChI

InChIKey=LSYBRGMTRKJATA-IVEWBXRVSA-N

InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C60H72N8O6
Molecular Weight	1001.2637
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT02765490 | https://www.ncbi.nlm.nih.gov/pubmed/24659881 | https://www.ncbi.nlm.nih.gov/pubmed/29736243

Odalasvir (previously known as ACH-3102) is a second-generation inhibitor of the nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It was reported that HCV NS5A is associated with interferon signaling related to HCV replication and hepatocarcinogenesis. HCV NS5A inhibitors efficiently inhibited HCV replication. It is known that HCV is a leading cause of hepatocellular carcinoma (HCC) in Japan and is one of the major causes of end-stage liver disease, HCC, and liver transplantation in the United States and Europe. Odalasvir completed phase II clinical trial, where was evaluated efficacy and safety of its combinations with AL-335, and simeprevir in the treatment of chronic hepatitis C Infection.

Originator

Approval Year

PubMed

Title	Date	PubMed
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.	2018-12	30070722
Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.	2018-10-22	30350297
Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.	2018-10	30118732
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.	2018-06	29736243
Hepatitis C virus NS5A inhibitors and drug resistance mutations.	2014-03-21	24659881
Meeting report: 26th International Conference on Antiviral Research.	2013-10	23973733

Patents

Sample Use Guides

In Vivo Use Guide

Odalasvir 25 mg tablet will be administered once daily.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:50:00 GMT 2025` Edited by `admin` on `Mon Mar 31 22:50:00 GMT 2025`
Record UNII	OVR52K7BDW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ODALASVIR

Official Name

English

odalasvir [INN]

Preferred Name

English

ODALASVIR [USAN]

Common Name

English

DIMETHYL N,N'-(1,4(1,4)-DIBENZENACYCLOHEXAPHANE-12,42-DIYLBIS(1HBENZIMIDAZOLE-5,2-DIYL((2S,3AS,7AS)-OCTAHYDRO-1H-INDOLE-2,1-DIYL)((2S)-3-METHYL-1-OXOBUTAN-1,2-DIYL)))BISCARBAMATE

Systematic Name

English

Odalasvir [WHO-DD]

Common Name

English

ACH-3102

Code

English

ACH-0143102

Code

English

CARBAMIC ACID, N,N'-(TRICYCLO(8.2.2.24,7)HEXADECA-4,6,10,12,13,15-HEXAENE-5,11-DIYLBIS(1H-BENZIMIDAZOLE-6,2-DIYL((2S,3AS,7AS)-OCTAHYDRO-1H-INDOLE-2,1-DIYL)((1S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL)))BIS-, C,C'-DIMETHYL ESTER

Systematic Name

English

Code System Code Type Description

PUBCHEM

71474517